Pfizer: Pfizer wins Korea nod for pediatric arthritis use of oral JAK inhibitor Xeljanz

Pfizer Korea has won national reimbursement for its oral JAK inhibitor Xeljanz (tofacitinib), expanding access to children with hard-to-treat juvenile arthritis as of last Tuesday.The new coverage, announced by the Ministry of Health and Welfare on March 25, applies to pediatric patients aged two to